NCT06799026 — David Avigan cancer vaccine trial
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Registry record
| Registry ID | NCT06799026 ↗ |
|---|---|
| Lead sponsor | David Avigan |
| Collaborators | Pfizer |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma |
| Enrollment | 25 participants (target) |
| Start date | 2025-01-31 |
| Primary completion | 2028-09-01 (est.) |
| Last registry update | 7 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06799026), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06799026?
NCT06799026 (A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma) is registered on ClinicalTrials.gov as Phase 1, sponsored by David Avigan.
Is NCT06799026 recruiting?
As of the 2026-05-07 registry update, NCT06799026 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06799026?
The lead sponsor is David Avigan. Collaborators: Pfizer.
What condition does NCT06799026 study?
The registered conditions are Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma. Primary completion is listed as 2028-09-01 (estimated).
Are results available for NCT06799026?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06799026.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.